Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Martina Bebin

Showing results (11-20 of 88) with videos related to

Pageof 9
Sort By:
Epilepsia Open|August 18, 2023
Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access programTyler E Gaston, E Martina Bebin, Gary R Cutter, et al.
Nature Reviews. Disease Primers|March 13, 2026
Tuberous sclerosis complexKellen Winden, E Martina Bebin, Shafali Jeste, et al.
Epilepsia|August 8, 2017
Interactions between cannabidiol and commonly used antiepileptic drugsTyler E Gaston, E Martina Bebin, Gary R Cutter, et al.
Journal of Neurosurgery|September 10, 2003
Complications of chronic vagus nerve stimulation for epilepsy in childrenMatthew D Smyth, R Shane Tubbs, E Martina Bebin, et al.
Epilepsia|December 27, 2021
Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trialElizabeth A Thiele, E Martina Bebin, Francis Filloux, et al.
Epilepsy & Behavior : E&B|June 21, 2019
Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsyRoy C Martin, Tyler E Gaston, Matthew Thompson, et al.
Epilepsy & Behavior : E&B|May 4, 2019
Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiolJerzy P Szaflarski, Kathleen Hernando, E Martina Bebin, et al.
Epilepsy & Behavior : E&B|August 6, 2019
Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access ProgramTyler E Gaston, E Martina Bebin, Gary R Cutter, et al.
Epilepsy & Behavior : E&B|September 2, 2020
Effects of highly purified cannabidiol (CBD) on fMRI of working memory in treatment-resistant epilepsyTyler E Gaston, Jane B Allendorfer, Sangeeta Nair, et al.
Epilepsy & Behavior : E&B|August 8, 2020
Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsyMatthew D Thompson, Roy C Martin, Leslie P Grayson, et al.
Pageof 9

Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Epilepsia Open|August 18, 2023
Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access programTyler E Gaston, E Martina Bebin, Gary R Cutter, et al.
Nature Reviews. Disease Primers|March 13, 2026
Tuberous sclerosis complexKellen Winden, E Martina Bebin, Shafali Jeste, et al.
Epilepsia|August 8, 2017
Interactions between cannabidiol and commonly used antiepileptic drugsTyler E Gaston, E Martina Bebin, Gary R Cutter, et al.
Journal of Neurosurgery|September 10, 2003
Complications of chronic vagus nerve stimulation for epilepsy in childrenMatthew D Smyth, R Shane Tubbs, E Martina Bebin, et al.
Epilepsia|December 27, 2021
Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open-label extension trialElizabeth A Thiele, E Martina Bebin, Francis Filloux, et al.
Epilepsy & Behavior : E&B|June 21, 2019
Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsyRoy C Martin, Tyler E Gaston, Matthew Thompson, et al.
Epilepsy & Behavior : E&B|May 4, 2019
Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiolJerzy P Szaflarski, Kathleen Hernando, E Martina Bebin, et al.
Epilepsy & Behavior : E&B|August 6, 2019
Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access ProgramTyler E Gaston, E Martina Bebin, Gary R Cutter, et al.
Epilepsy & Behavior : E&B|September 2, 2020
Effects of highly purified cannabidiol (CBD) on fMRI of working memory in treatment-resistant epilepsyTyler E Gaston, Jane B Allendorfer, Sangeeta Nair, et al.
Epilepsy & Behavior : E&B|August 8, 2020
Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsyMatthew D Thompson, Roy C Martin, Leslie P Grayson, et al.
Pageof 9